INCYSUS THERAPEUTICS TO PRESENT AT THE 2020 SOLEBURY TROUT VIRTUAL INVESTOR CONFERENCE

New York, New York, UNITED STATES


NEW YORK, April 06, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a clinical-stage biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the treatment of cancers, today announced that the Company will present at the 2020 Solebury Trout Virtual Investor Conference on Tuesday, April 7th.  William Ho, President and Chief Executive Officer of Incysus Therapeutics, will present a company update.  During the 25-minute presentation, participants will be able to submit questions electronically with answers provided afterwards.

WHO:William Ho, President and Chief Executive Officer, Incysus Therapeutics
WHAT:Incysus Therapeutics at the Solebury Trout Virtual Investor Conference
WHEN:Tuesday, April 7, 2020 at 1:00 p.m. Eastern Time
LOGIN:To access the presentation, please login here


About Solebury Trout

Solebury Trout provides investor relations, corporate communications and market access to private and public companies across industry sectors. Solebury Capital advises corporate and financial sponsor clients, offering independent advice, experienced judgment and transaction management services during the capital-raising process.

About Incysus Therapeutics, Inc.
Incysus is focused on delivering a novel off-the-shelf cell therapy for the treatment of cancer. By using genetically modified gamma-delta (γδ) T cells, the Company’s technology addresses the challenges that immunotherapies face targeting cold, low mutation cancers. Incysus’ immuno-oncology programs include activated and gene-modified adoptive cellular therapies that protect cells from chemotherapy and allow novel combinations to disrupt the tumor microenvironment and more selectively target cancer cells. The Company’s first clinical program delivering a genetically modified γδ T cell for the treatment of newly diagnosed glioblastoma (GBM) can be found here: (NCT04165941) and its second clinical program with an allogeneic γδ T cell therapy for leukemia and lymphoma patients undergoing allogeneic stem cell transplantation can be found here: (NCT03533816). For more information about the Company and its programs, visit www.incysus.com.

Forward Looking Statements
Certain statements herein concerning the Company’s future expectations, plans and prospects, including without limitation, the Company’s current expectations regarding its business strategy, product candidates, and clinical development process and timing, constitute forward-looking statements. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” the negative of these and other similar expressions are intended to identify such forward looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond the Company’s control. Consequently, actual future results may differ materially from the anticipated results expressed in such statements. In the case of forward-looking statements regarding investigational product candidates and continuing further development efforts, specific risks which could cause actual results to differ materially from the Company’s current expectations include: scientific, regulatory and technical developments; failure to demonstrate safety, tolerability and efficacy; final and quality controlled verification of data and the related analyses; expense and uncertainty of obtaining regulatory approval, including from the U.S. Food and Drug Administration; and the Company’s reliance on third parties, including licensors and clinical research organizations. Do not place undue reliance on any forward-looking statements included herein, which speak only as of the date hereof and which the Company is under no obligation to update or revise as a result of any event, circumstances or otherwise, unless required by applicable law.

Contact:
William Ho
Incysus Therapeutics, Inc.
+1 646.600.6GDT
info@incysus.com
www.incysus.com